Media coverage about Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) has trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Valeant Pharmaceuticals International earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.0167186343943 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have effected Accern’s scoring:
Several equities analysts recently issued reports on VRX shares. Zacks Investment Research cut Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a research report on Thursday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. BidaskClub raised Valeant Pharmaceuticals International from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Piper Jaffray Companies reaffirmed a “sell” rating and issued a $14.00 price objective on shares of Valeant Pharmaceuticals International in a report on Sunday, September 17th. Finally, Vetr raised Valeant Pharmaceuticals International from a “strong sell” rating to a “sell” rating and set a $12.46 price target on the stock in a research note on Monday, September 18th. Five analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $17.71.
Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at 13.39 on Friday. The firm’s market capitalization is $4.67 billion. The firm has a 50-day moving average of $13.96 and a 200 day moving average of $13.55. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $24.30.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The company had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. During the same period in the prior year, the firm earned ($0.88) earnings per share. The company’s revenue was down 7.7% on a year-over-year basis. Analysts predict that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.
In other news, Director Schutter Richard U. De acquired 10,000 shares of Valeant Pharmaceuticals International stock in a transaction on Monday, August 21st. The shares were purchased at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the purchase, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 5.87% of the company’s stock.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/15/valeant-pharmaceuticals-international-vrx-given-coverage-optimism-score-of-0-15.html.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.